Hypothesis

In aged tissues, the accumulation of H3K27me3 at bivalent promoters creates a higher epigenetic barrier that must be overcome by increased KDM6 demethylase activity to permit oncogene expression, whereas young‑onset cancers arise from bivalent loci already poised with lower H3K27me3 and thus require less KDM6 flux. Consequently, late‑onset tumors will exhibit greater sensitivity to pharmacological KDM6 inhibition, while early‑onset tumors will rely more on KDM5‑mediated mechanisms of therapy resistance and immune evasion.

Mechanistic Rationale

1. Epigenetic barrier model – Aging drives hypermethylation of CpG islands within bivalent promoters, broadening and intensifying H3K27me3 domains (see [2]). This raises the threshold of H3K27me3 removal needed to allow transcription factors (e.g., SOX9) to access DNA. KDM6A/B (UTX/JMJD3) must therefore operate at higher catalytic rates or be upregulated to achieve the permissive H3K27me3/H3K4me3 balance characteristic of cancer‑specific bivalent promoters (CSBPs) [1].

2. Compensatory KDM5 upregulation – To counteract the increased demethylase load, aged cells may boost KDM5 activity, preserving global H3K4me2/3 homeostasis and contributing to the broad therapy‑resistance phenotype observed across cancers [3]. KDM5‑driven H3K4 demethylation can also limit aberrant transcription initiation, forcing the cell to depend on KDM6 for oncogene activation.

3. Therapeutic implication – If late‑onset tumors are KDM6‑addicted, then KDM6 inhibitors (e.g., GSK‑J4) should reduce persister cell numbers and impair tumor initiation more strongly in aged‑derived models than in young‑derived counterparts, mirroring the effect seen in triple‑negative breast cancer [4]. Early‑onset tumors, needing less H3K27me3 removal, would be relatively resistant to KDM6 blockade but vulnerable to KDM5 inhibition or to agents that disrupt KDM5‑immune interactions.

Testable Predictions

• Prediction 1: In paired normal epithelial cells from young (<35 y) and old (>65 y) donors transformed with identical oncogenic stimuli (e.g., KRAS^G12D + p53 loss), old‑derived cells will show higher basal KDM6A/B mRNA/protein levels and greater sensitivity to GSK‑J4 (IC50 shift ≥2‑fold) compared with young‑derived cells.
• Prediction 2: CRISPR‑mediated knock‑down of KDM6 in old‑derived transformed cells will markedly reduce SOX9 and other CSBP‑linked oncogene expression and colony‑forming efficiency, whereas the same knock‑down in young‑derived cells will produce a modest effect.
• Prediction 3: Pharmacologic inhibition of KDM5 (e.g., CPI‑455) will synergize with GSK‑J4 in young‑derived tumors but show limited additivity in old‑derived tumors, reflecting divergent dependency profiles.
• Prediction 4: Immunoprofiling of tumors derived from aged vs young donors will reveal that KDM6 inhibition in old tumors increases antigen presentation and CD8+ T‑cell infiltration, while KDM5 inhibition in young tumors shifts macrophage polarization from M2 to M1.

Experimental Approach

• Generate isogenic transformation models using hTERT‑HRPECs from young and old donors, introduce KRAS^G12D and TP53 knockout via CRISPR.
• Validate bivalent promoter states by ChIP‑seq for H3K27me3 and H3K4me3 at SOX9 and other CSC loci.
• Measure KDM6/KDM5 expression (qPCR, Western) and activity (demethylase assays).
• Treat with GSK‑J4, CPI‑455, alone and combined; assess viability, sphere formation, and in vivo tumorigenicity in NSG mice.
• Perform RNA‑seq and ATAC‑seq to trace transcriptional and chromatin accessibility changes.
• Use flow cytometry and immunohistochemistry to evaluate immune cell infiltrates and macrophage phenotypes.

Potential Outcomes and Interpretation

If the data confirm heightened KDM6 dependence in aged‑derived tumors, it would substantiate the notion that aging creates a distinct epigenetic oncogenic landscape, offering a biomarker‑driven rationale for age‑stratified epigenetic therapy. Conversely, a lack of age‑dependent difference would refute the barrier model and suggest that other cooperating alterations (e.g., metabolic reprogramming) dominate transformation irrespective of promoter methylation status.